Get the Stockscreener App
0.2684
1.67%
-0.0066
Intensity Therapeutics Inc stock is traded at $0.2684, with a volume of 1.16M.
It is down -1.67% in the last 24 hours and up +13.14% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.275
Open:
$0.27
24h Volume:
1.16M
Relative Volume:
0.29
Market Cap:
$13.10M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.2272
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
-10.43%
1M Performance:
+13.14%
6M Performance:
-88.39%
1Y Performance:
-93.67%
1-Day Range:
$0.265
$0.2837
1-Week Range:
$0.265
$0.3046
52-Week Range:
$0.1853
$4.3398
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.2681 | 13.27M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.04 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.06 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.34 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.16 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
337.45 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Price momentum metrics for Intensity Therapeutics Inc. explainedMarket Trend Review & Weekly Momentum Stock Picks - Newser
Intensity Therapeutics Inc. stock trend forecast2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Is it too late to sell Intensity Therapeutics Inc.July 2025 Spike Watch & Accurate Intraday Trade Tips - Newser
Using data models to predict Intensity Therapeutics Inc. stock movementQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Intensity Therapeutics shares rise 1.82% premarket after announcing participation in H.C. Wainwright 27th Annual Global Investment Conference. - AInvest
How to interpret RSI for Intensity Therapeutics Inc. stock2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Developing predictive dashboards with Intensity Therapeutics Inc. data2025 Geopolitical Influence & Weekly Breakout Watchlists - Newser
Using RSI to spot recovery in Intensity Therapeutics Inc.Weekly Investment Report & Precise Swing Trade Entry Alerts - Newser
What candlestick patterns are forming on Intensity Therapeutics Inc.Buy Signal & Verified Short-Term Plans - Newser
What MACD and RSI say about Intensity Therapeutics Inc.Rate Hike & Growth Oriented Trading Recommendations - Newser
Tools to monitor Intensity Therapeutics Inc. recovery probabilityLong Setup & Risk Controlled Daily Trade Plans - Newser
Can Intensity Therapeutics Inc. hit a new high this monthFed Meeting & Real-Time Buy Signal Alerts - Newser
Intensity Therapeutics Inc. stock chart pattern explainedJuly 2025 EndofMonth & Intraday High Probability Alerts - Newser
Tools to assess Intensity Therapeutics Inc.’s risk profilePortfolio Update Report & Free Risk Controlled Daily Trade Plans - Newser
Intensity Therapeutics Inc. stock daily chart insightsPortfolio Return Summary & Short-Term Trading Alerts - Newser
Will Intensity Therapeutics Inc. benefit from rate cuts2025 Risk Factors & Stock Portfolio Risk Management - khodrobank.com
How sentiment analysis helps forecast Intensity Therapeutics Inc.Treasury Yields & Smart Investment Allocation Insights - Newser
Will Intensity Therapeutics Inc. outperform the market in YEARJuly 2025 Final Week & AI Driven Price Predictions - khodrobank.com
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - PR Newswire
Pattern recognition hints at Trevi Therapeutics Inc. upside2025 Major Catalysts & AI Powered Buy/Sell Recommendations - Newser
What drives Intensity Therapeutics Inc.’s stock pricePortfolio Risk Report & Weekly Setup with High ROI Potential - khodrobank.com
What to expect from Intensity Therapeutics Inc. in the next 30 daysIndex Update & Free Community Supported Trade Ideas - Newser
What earnings revisions data tells us about Intensity Therapeutics Inc.2025 Price Action Summary & Momentum Based Trading Ideas - Newser
Is There Enough Volume to Lift Intensity Therapeutics Inc.New Guidance & High Accuracy Swing Trade Signals - beatles.ru
Evaluating Intensity Therapeutics Inc. with trendline analysis2025 Historical Comparison & Stock Portfolio Risk Management - Newser
Can trapped investors hope for a rebound in Intensity Therapeutics Inc.Market Performance Recap & Smart Swing Trading Alerts - Newser
Can momentum traders help lift Intensity Therapeutics Inc.Earnings Miss & Community Supported Trade Ideas - Newser
Can a trend reversal in Intensity Therapeutics Inc. lead to recoveryJuly 2025 Institutional & Technical Confirmation Alerts - Newser
Real time scanner hits for Intensity Therapeutics Inc. explainedTrade Analysis Summary & Verified Entry Point Detection - Newser
Published on: 2025-08-30 21:55:29 - Newser
Is now a turning point for Intensity Therapeutics Inc.2025 Price Targets & Daily Market Momentum Tracking - Newser
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):